Similarly, increased p53 expression in 85 MDS cases with del5q was associated with a higher likelihood of AML formation, shorter OS, and lower cytogenetic response rate to lenalidomide treatment (24). This evidence concerns the gene TP53 and myelodysplastic syndrome.